Calls for papers
-
MannKind Corporation will develop a dry powder formulation of Thirona Bio’s FBM5712 ALK-5 kinase inhibitor, the companies have announced. The deal gives MannKind the option to license the compound for the treatment of fibrotic diseases in the lung and… Read more . . .
-
Nuance Pharma will pay $25 million in cash, plus equity in its parent company Nuance Biotech valued at $15 million, as well as potential milestone payments worth up to $179 million to Verona Pharma for… Read more . . .
-
Proveris Scientific, a specialist in aerosol drug delivery testing, announced that it has hired engineer Prateek Nath to “to design and build a wide variety of research-grade prototypes and run experiments on these prototypes to… Read more . . .
-
Nuformix said that it has received a Notice of Allowance for US Patent Application No. 17/051,592 titled, “Crystalline Tranilast Salts and Their Pharmaceutical Use.” The company has already been granted one patent covering crystalline forms… Read more . . .
-
Noveome Biotherapeutics said that a Phase 1 safety study of its intranasal ST266 secretome in glaucoma suspect patients demonstrated no serious adverse events at doses up to 400 µL per day over 28 days. The… Read more . . .
-
The FDA is touting its June 1, 2021 approval of Sandoz’s ANDA for an albuterol sulfate MDI for the treatment of asthma, saying, “The FDA recognizes the increased demand for certain products during the COVID-19… Read more . . .
-
Lupin has announced the US launch of an authorized generic version of Sunovion’s Brovana arformoterol tartrate inhalation solution for the treatment of COPD. The FDA tentatively approved the company’s ANDA for the inhalation solution in… Read more . . .
-
Evoke Pharma said that the United States Patent and Trademark Office (USPTO) has issued US patent No. 11,020,361 (“Nasal Formulations of Metoclopramide”) covering methods of use for Gimoti metoclopramide nasal spray for the treatment of gastroparesis… Read more . . .
-
According to Liquidia, the FDA has accepted the company’s resubmitted NDA for LIQ861 treprostinil DPI for the treatment of pulmonary arterial hypertension and has set a PDUFA goal date of November 7, 2021. Liquidia initially… Read more . . .
-
Aerosol testing specialist Proveris Scientific has named Maria L. Smith as Director, Application and Business Development for Proveris Laboratories. Smith has extensive experience in OINDP spray characterization, first at DPT Laboratories and then at Renaissance Lakewood.… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK